Search Result

Results for "

Appetite Regulation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endogenous Metabolite (1) Histone Methyltransferase (1) Neuropeptide FF Receptor (2) Neuropeptide Y Receptor (1) Orexin Receptor (OX Receptor) (2)
By Research Areas:	Cardiovascular Disease (1) Endocrinology (1) Infection (1) Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1339B

Orexin B, human acetate Human orexin B acetate	Orexin Receptor (OX Receptor)	Cardiovascular Disease Neurological Disease
Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with K_i of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine .

HY-120619

BMS-193885	Neuropeptide Y Receptor	Neurological Disease Endocrinology
BMS-193885 is a selective neuropeptide Y1 receptor antagonist (K_i=3.3 nM) that competitively blocks the receptor to inhibit NPY-mediated appetite regulation signaling pathways, reduce food intake and inhibit weight gain. BMS-193885 has good blood-brain barrier penetration and is mainly used in the study of obesity and related metabolic diseases .

HY-106224B

Orexin A (human, rat, mouse) acetate 5+ Cited Publications Hypocretin-1 (human, rat, mouse) acetate	Orexin Receptor (OX Receptor)	Neurological Disease
Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging .

HY-Y0079

D-Phenylalanine	Endogenous Metabolite	Infection
D-Phenylalanine is an atypical D-amino acid and an inhibitor of bacterial biofilm formation. D-Phenylalanine mainly replaces D-alanine (D-Ala) by incorporating into the fourth and fifth positions of bacterial peptidoglycan (PG), changing the cell wall structure, enhancing bacterial acid resistance and affecting biofilm formation. D-Phenylalanine may promote the secretion of peptide tyrosine tyrosine (PYY) in mammals by activating the intestinal GPR109B receptor. D-Phenylalanine can inhibit the maturation of microbial biofilms and promote the release of specific hormones. It can be used for antibacterial preservation, improving the yield of probiotics in the food industry, and studying appetite regulation and blood sugar control in metabolic diseases such as diabetes .

HY-P2025

JMV 236	Histone Methyltransferase	Neurological Disease
JMV 236 is a cholecystokinin antagonist with appetite-suppressing activity. JMV 236 affects the regulation of food intake through the interaction of the intestinal endogenous peptide PrRP and the CCK1 receptor. The administration of JMV 236 activates PrRP neurons located in the NTS, thereby enhancing its appetite-suppressing effect. JMV 236 has significant effects on areas of the central nervous system associated with food intake, especially during states of starvation .

HY-P10379

palm-PrRP31	Neuropeptide FF Receptor	Others Neurological Disease
palm-PrRP31 is a potent dual receptor agonist for both GPR10 (EC₅₀=72 pM) and NPFF-R2. palm-PrRP31 activates downstream signaling pathways through binding to its receptors, GPR10 and NPFF-R2, which results in reduced appetite and increased energy expenditure. Utilizing palm-PrRP31 facilitates the study of the mechanism of action in the nervous system, thereby elucidating the complex biological processes that regulate appetite and energy expenditure .

HY-P10380

palm11-PrRP31	Neuropeptide FF Receptor	Neurological Disease
palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC₅₀=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	3,068 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,068 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

3,068 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,068 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Target	Research Area